Abstract
Enzalutamide, which inhibits androgen receptor signaling at multiple steps, was approved for metastatic castration-resistant prostate cancer (mCRPC) in Japan in 2014. Since then, we have treated mCRPC patients with enzalutamide; however, limited information is available as to clinical outcomes of enzalutamide in Japanese patients. In this chapter, I will review the efficacy, safety, and pharmacokinetics of enzalutamide in Japanese patients first from clinical trials, including the PREVAIL and phase I/II study in Japanese patients and then from retrospective studies of real-world data in Japan. Treatment effects and safety of enzalutamide in Japanese patients were generally consistent with the overall results from non-Japanese populations. However, in daily clinical practice, the patients often complain of such difficulties as swallowing due to the big size of capsule, fatigue, and appetite loss. In order to continue this effective enzalutamide therapy without discontinuation due to these subjective symptoms, dose reduction seems to be the best way.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Huggins C, Hodges CV. Studies on prostate cancer 1: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.
Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.
Scher HI, Sawyers CL. Biology of progressive castration-resistant prostate cancer: directed therapies targeting the androgen- receptor signaling axis. J Clin Oncol. 2005;23:8253–61.
Montgomery RB, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.
Cai C, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503–13.
Linja MJ, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61:3550–5.
Chen CD, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.
Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
Jung ME, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010;53:2779–96.
Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.
Scher HI, et al. Antitumour activity of MDV3100 in castration- resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437–46.
Beer TM, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–4.
Kimura G, et al. Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: a post-hoc analysis of the placebo-controlled PREVAIL trial. Int J Urol. 2016;23:395–403.
Akaza H, et al. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. Int J Clin Oncol. 2016;21:773–82.
Yamasaki M, et al. Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer. Anticancer Res. 2016;36:361–5.
Igarashi A, et al. Initial experience of the enzalutamide treatment for castration-resistant prostate cancer. Jpn J Urol. 2016;107:155–61. (Japanese).
Kato H, et al. Consequences of an early PSA response to enzalutamide treatment for Japanese patients with metastatic castration-resistant prostate cancer. Anticancer Res. 2016;36:6141–50.
Terada N, et al. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol. 2016;21:1155–61.
Iguchi T, et al. Management of enzalutamide-related adverse events for castration resistant prostate cancer patients. Jpn J Urol Surg. 2015;28:1685–91. (Japanese).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kimura, G. (2018). Enzalutamide Therapy for mCRPC in Japanese Men. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_24
Download citation
DOI: https://doi.org/10.1007/978-981-10-7013-6_24
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7012-9
Online ISBN: 978-981-10-7013-6
eBook Packages: MedicineMedicine (R0)